- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03086174
Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma
A Phase Ib,Open,Mono-center,Dose-escalation,Tolerability and Pharmacokinetic Study of Recombinant Humanized Anti-PD-1 mAb for Injection in Combination With Axitinib in Patients With Advanced Kidney Cancer and Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase Ib, open, mono-center, dose-escalation, tolerability and pharmacokinetic study evaluating the Recombinant Humanized Anti-PD-1 mAb for Injection in combination with Axitinib in patients with advanced kidney cancer and melanoma who have failed in routine systemic treatment.The study will be conducted in 2 parts: dose escalation and cohort expansion.
18 to 24 patients will be enrolled in dose escalation part.This part is to analyze safety and efficacy of the humanized anti-PD-1 antibody in combination with axitinib and to confirm dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended dose (RD). After finishing the dose escalation part, we will enroll other patients for each tumor types of recommended dose group to ensure each group have 10 patients. This part is to further analyze safety and efficacy of the humanized anti-PD-1 antibody.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Beijing Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and Female aged between 18 and 75 years are eligible;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- At least received first-line treatment but appeared disease progression or intolerance, and a diagnosis of an advanced kidney Cancer and melanoma confirmed by pathology (Remark: Treatment intolerance including 1) The main organ function of the patient is evaluated by the doctor that can not be treated by the first-line standard;2) Patients received a first-line treatment with a 3/4 adverse reaction;3) Patients reject first-line treatment, etc)
- Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);
- At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions)
- Predicted survival >=3 months;
- Brain or meningeal metastases must be disposed with surgery or radiation, and be stable clinically for at least 3 months (prior systemic steroids was allowed, but concurrent administration of systemic steroids with the study drug is excluded).
- Screening laboratory values must meet the following criteria(within past 14 days):
hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ µL; platelets ≥ 100 x 10^3/ µL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN,creatinine clearance >50ml/min (Cockcroft-Gault equation) INR, aPTT≤1.5 x ULN; Urine protein + 1 or less, if the urine protein > 1 +, need to collect 24 hours urinary protein determination, the total amount should be 1 gram or less
- Without systemic steroids within past 4 weeks
- Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.
- Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
Exclusion Criteria:
- Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody and Axitinib
- Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its components
- Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- Pregnant or nursing;
- Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml);
- HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml)
- History with active tuberculosis;
- Associated with clinical symptoms or symptomatic treatment of pleural effusion or ascites;
- Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism;
- Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, heart block >II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm).
- Evidence with active CNS disease;
- Prior treatment with bone marrow stimulating factors,such as CSF (colony stimulating factor), EPO (erythropoietin), within past 1 weeks;
- Prior live vaccine therapy within past 4 weeks;
- Received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- Prior major surgery within past 4 weeks (diagnostic surgery excluded).
- Psychiatric medicines abuse without withdrawal, or history of psychiatric illness.
- Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix.
- Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: humanized anti-PD-1monoclonal antibody
humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
|
humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 3 years
|
Safety assessments including vital signs, laboratory tests, and adverse event monitoring
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PD-1 receptor occupancy of blood
Time Frame: 3 years
|
To test the PD - 1 receptor share in the blood
|
3 years
|
Objective Response Rate (ORR) by irRC and RECIST 1.1
Time Frame: 3 years
|
The treatment effect of JS001 in combination with axitinib, will be assessed using irRC and RECIST 1.1 to determine tumor response.
|
3 years
|
Duration of Response (DOR) by irRC and RECIST 1.1
Time Frame: 3 years
|
The treatment effect of JS001 in combination with axitinib, will be assessed using irRC and RECIST 1.1 to determine duration of response.
|
3 years
|
Disease Control Rate (DCR) by irRC and RECIST 1.1
Time Frame: 3 years
|
The treatment effect of JS001 in combination with axitinib, will be assessed using irRC and RECIST 1.1 to determine disease control rate.
|
3 years
|
Time to response (TTR) by irRC and RECIST 1.1
Time Frame: 3 years
|
The treatment effect of JS001 in combination with axitinib, will be assessed using irRC and RECIST 1.1 to determine time to response.
|
3 years
|
Progression-free survival(PFS) by irRC and RECIST 1.1
Time Frame: 3 years
|
The treatment effect of JS001 in combination with axitinib, will be assessed using irRC and RECIST 1.1 to determine progression-free survival time.
|
3 years
|
Overall survival (OS) by irRC and RECIST 1.1
Time Frame: 3 years
|
The treatment effect of JS001 in combination with axitinib, will be assessed using irRC and RECIST 1.1 to determine overall survival.
|
3 years
|
PK Parameter: Maximum Plasma Concentration (Cmax)
Time Frame: 3 years
|
Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb) in combination with axitinib
|
3 years
|
PK Parameter: Peak Time (Tmax)
Time Frame: 3 years
|
Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: t1/2
Time Frame: 3 years
|
t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: Area Under the Curve (AUC)
Time Frame: 3 years
|
Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: Plasma clearance (CL)
Time Frame: 3 years
|
Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: Apparent volume of distribution (V)
Time Frame: 3 years
|
Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: Minimum Plasma Concentration (Cmin)
Time Frame: 3 years
|
Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: Average Plasma Concentration (Cav)
Time Frame: 3 years
|
Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: degree of fluctuation (DF)
Time Frame: 3 years
|
degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
PK Parameter: Apparent volume of distribution of steady state (Vss)
Time Frame: 3 years
|
Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb in combination with axitinib
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
correlation analysis of PD-L1 expression of tumor and ORR
Time Frame: 3 years
|
correlation analysis of PD-L1 expression of tumor and objective response rate
|
3 years
|
correlation analysis of PD-L1 expression of tumor and DOR
Time Frame: 3 years
|
correlation analysis of PD-L1 expression of tumor and duration of response
|
3 years
|
correlation analysis of PD-L1 expression of tumor and DCR
Time Frame: 3 years
|
correlation analysis of PD-L1 expression of tumor and disease control rate
|
3 years
|
correlation analysis of PD-L1 expression of tumor and TTR
Time Frame: 3 years
|
correlation analysis of PD-L1 expression of tumor and time to response
|
3 years
|
correlation analysis of PD-L1 expression of tumor and PFS
Time Frame: 3 years
|
correlation analysis of PD-L1 expression of tumor and progression-free survival
|
3 years
|
correlation analysis of PD-L1 expression of tumor and OS
Time Frame: 3 years
|
correlation analysis of PD-L1 expression of tumor and overall survival
|
3 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Erratum In: Lancet. 2012 Nov 24;380(9856):1818.
- Du Four S, Maenhout SK, De Pierre K, Renmans D, Niclou SP, Thielemans K, Neyns B, Aerts JL. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology. 2015 Jan 22;4(4):e998107. doi: 10.1080/2162402X.2014.998107. eCollection 2015 Apr.
- Li S, Wu X, Yan X, Zhou L, Chi Z, Si L, Cui C, Tang B, Mao L, Lian B, Wang X, Bai X, Dai J, Kong Y, Tang X, Feng H, Yao S, Flaherty KT, Guo J, Sheng X. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J Immunother Cancer. 2022 Feb;10(2):e004036. doi: 10.1136/jitc-2021-004036.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Melanoma
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Antibodies, Monoclonal
Other Study ID Numbers
- Junshi-JS001-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Melanoma
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)United States
-
Regeneron PharmaceuticalsBristol-Myers SquibbCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Metastatic Melanoma | Advanced Non-hematologic MalignanciesUnited States
-
University of Colorado, DenverMerck Sharp & Dohme LLCActive, not recruitingStage IV Melanoma | Advanced Melanoma | Stage III MelanomaUnited States
-
Yana NajjarBristol-Myers Squibb; PfizerActive, not recruitingUnresectable Melanoma | Advanced MelanomaUnited States
-
Shanghai Junshi Bioscience Co., Ltd.UnknownMetastatic Melanoma | Advanced MelanomaChina
-
Azienda Ospedaliera di PerugiaNot yet recruitingAdvanced Melanoma | Early MelanomaItaly, Sweden, France, Germany, Netherlands, Poland, Spain
Clinical Trials on humanized anti-PD-1 monoclonal antibody Toripalimab
-
Shanghai Junshi Bioscience Co., Ltd.UnknownBladder Urothelial CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.UnknownMetastatic Melanoma | Advanced MelanomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Completed
-
Shanghai Junshi Bioscience Co., Ltd.Completed
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States
-
Shanghai Junshi Bioscience Co., Ltd.Iqvia Pty Ltd; TopAlliance Biosciences, Inc.Active, not recruitingAdvanced MalignanciesUnited States
-
Shanghai Junshi Bioscience Co., Ltd.UnknownMelanoma | Urological CancerChina
-
Genor Biopharma Co., Ltd.RecruitingAlveolar Soft Part SarcomaChina
-
Shanghai Henlius BiotechRecruiting
-
Genor Biopharma Co., Ltd.RecruitingPeripheral T Cell LymphomaChina